GV-971 is an orally administered mixture of acidic linear oligosaccharides derived from marine brown algae. Preclinical studies on its mechanism of action show that GV-971 improved the cognitive function by inhibiting neuroinflammation via targeting dysbiosis of gut microbiota in AD transgenic mouse models. In a completed 36-week Phase 3 clinical trial conducted in China, GV-971 showed rapid initial gains in cognition with sustained improvement across the study in mild-to-moderate Alzheimer’s patients that was statistically significant comparing to the placebo. Green Valley’s novel therapy was approved by the National Medical Products Administration (NMPA) and launched in China last year.
Building on Green Valley’s successful application for GV-971 as the first Alzheimer’s drug approved in China in 17 years, MMS and Green Valley partnered closely to support an additional Phase 3 study and development plan to meet the requirements of US regulations.
“With its novel mechanism of action and positive results in one Phase 3 study, MMS is excited to be part of a program that is advancing new therapies in an indication that has been relentlessly challenging over the last few decades, and we thank Green Valley for their continued trust in us,” says Ben Kaspar, Global Regulatory Affairs Manager, MMS.
Dr. Uma Sharma, Chief Scientific Officer at MMS, added, “MMS has a well-established history within neuroscience and strategic support of these indications is a tradition in our portfolio. We are proud to see many international sponsors benefitting from this expertise in recent times.”
With this announcement, Green Valley can now begin the large-scale Phase 3 clinical trial in the United States as part of a global trial that seeks to enroll more than 2,000 patients with mild-to-moderate Alzheimer’s across North America, Europe and Asia.
“We are pleased with the FDA’s decision to approve our IND and proceed to Phase 3 clinical trials, and we could not have made it to this point without the knowledgeable and nimble support of MMS,” says Dr. Meiyu Geng, inventor of GV-971. “From the onset of our collaboration, MMS provided our team with in-depth, regulatory and operational support and a level of care that is rarely seen with other specialty CROs.”
The Phase 3 clinical trial is planned to be completed in 2024, and the new drug registration application (NDA) submission is expected by 2025.
Learn more about regulatory support at MMS: https://www.mmsholdings.com/regulatory-affairs-and-operations/
About MMS Holdings
MMS is an award-winning, data-focused CRO that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating, and the company has been recognized as a leading CRO in Global Health & Pharma’s international awards programs for the last three consecutive years. For more information, visit www.mmsholdings.com or follow MMS on LinkedIn.
About Green Valley
Shanghai Green Valley Pharmaceuticals is an innovative Chinese pharmaceutical company that pioneers new treatment strategies in the area of chronic and complex diseases. The company upholds the sacred mission of “Developing Only the Medicine that Human Beings Most Hope for”, explores the pathogenesis of chronic and complex diseases with a holistic view of treatment, and focuses on breakthrough innovation in research and development of carbohydrate drugs. Green Valley is committed to becoming a global leader in carbohydrate drug innovation, providing safer and more effective drugs for patients with chronic and complex diseases, and providing better choice of treatment for diseases and improving the quality of life.
Green Valley Pharmaceuticals was founded in 1997 and is headquartered in Zhangjiang Hi-Tech Park in Shanghai, China. It is focused on advancing research programs in neuropsychiatric diseases, cancer, cardiovascular diseases, metabolic diseases and autoimmune diseases. It has 1,500 employees in China and operates a subsidiary in the United States. It has built the world’s first large-scale carbohydrate compound library, the first carbohydrate drug API and processing facility, and the world’s leading R&D pipeline for carbohydrate drug products. For more information, visit greenvalleypharma.com.